Solventum Corporation

Valuation Analysis

About the Company

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agent

Solventum Corporation Stock at a Glance

Solventum Corporation (SOLV) is currently trading at $78.87 with a market capitalization of $13.7B. The trailing P/E ratio stands at 9.65x, with a forward P/E of 11.19x. The 52-week range spans from $62.38 to $88.20; the current price is 10.6% below the yearly high. Year-over-year revenue growth stands at -3.0%. The net profit margin stands at 17.33%.

💰 Dividend

Solventum Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

13 analysts rate Solventum Corporation (SOLV) on consensus: Buy. The average price target is $82.15, implying +4.16% from the current price. Analyst price targets range from $60.00 to $100.00.

Solventum Corporation: The Investment Case in Detail

Solventum Corporation (SOLV) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Return on equity of 34.79% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 17.33%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

The Bear Case

Revenue is contracting at -3% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

Valuation in Context

The PEG ratio at 1.22 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (5.15%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Solventum Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.